Polynucleotides encoding anticoagulant fusion proteins

Details Polynucleotides encoding anticoagulant fusion proteins Polynucleotides encoding anticoagulant fusion proteins

2007-06-21

2009-11-24

Szperka, Michael (Department: 1644)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S023100, C536S023400, C536S023530

Reexamination Certificate

active

07622457

ABSTRACT:
This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

REFERENCES:
patent: 4208479 (1980-06-01), Zuk
patent: 4912207 (1990-03-01), Majerus
patent: 5256770 (1993-10-01), Glaser
patent: 5298599 (1994-03-01), Rezaie
patent: 5466668 (1995-11-01), Glaser
patent: 5506134 (1996-04-01), Soule
patent: 5574007 (1996-11-01), Zushi
patent: 5589173 (1996-12-01), O'Brien
patent: 5827824 (1998-10-01), Light
patent: 5843442 (1998-12-01), Soule
patent: 5863760 (1999-01-01), Light
patent: 5874407 (1999-02-01), Kelley
patent: 5916874 (1999-06-01), Fujiwara
patent: 5986065 (1999-11-01), Wong
patent: 6063763 (2000-05-01), Light
patent: 6274142 (2001-08-01), O'Brien
patent: 6555319 (2003-04-01), Wong
patent: 6632791 (2003-10-01), Light et al.
patent: 2006/0166284 (2006-07-01), Light
patent: 2008/0020965 (2008-01-01), Light
patent: WO 88/07543 (1988-10-01), None
patent: WO 88/09811 (1988-12-01), None
patent: WO 90/10081 (1990-09-01), None
patent: WO 98/40408 (1998-09-01), None
patent: WO 01/70984 (2001-09-01), None
patent: WO 01/98352 (2001-12-01), None
patent: WO 03/057911 (2003-05-01), None
Janeway et al.,Immunobiology, 3rded., Garland Publishin Inc., 1997, pp. 3:7-3:9.
Amit et al., 1986,Science 233, 747-53.
Rudikoff et al.,Proc. Natl. Acad. Sci. USA 79, 1979-83, 1982.
Stedman's Medical dictionary, 27thed., 2000, definition of synergism, downloaded Oct. 26, 2006 from thomsonhc.com, 2 pages.
On-line Medical dictionary definition of synergy, downloaded Oct. 26, 2006 from cancerweb.ncl.ac.uk, 1 page.
Skolnick et al.,Trends in Biotechnology 18, 34-39, 2000.
Whisstock et al.,Quarterly Review of Biophysics 36, 307-40, 2003.
Fuentes-Prior et al., “Structural Basis for the anticoagulant Activity of the Thrombin-thrombomodulin Complex,”Letters to Nature 404, 518-25, Mar. 30, 2000.
Clarke et al., The Short Loop Between epidermal Growth Factor-like Domains 4 and 5 is Critical for Human Thrombomodulin Function,J. Biol. Chem. 268, 6309-15, Mar. 25, 1993.
Hall et al., “Thrombin Interacts with Thrombomodulin, Protein C, and Thrombin-activatable Fibrinolysis Inhibitor via Specific and Distinct Domains,”J. Biol. Chem. 274, 22510-16, Sep. 3, 1999.
Nagashima et al., “Alanine-scanning Mutagenesis of the epidermal Growth Factor-like Domains of Human Thrombomodulin Identifies Critical Residues for its Cofactor Activity,”J. Biol. Chem. 268, 2888-92, Feb. 5, 1993.
Wang et al., “Elements of the Primary Structure of thrombomodulin Required for Efficient Thrombin-activable Fibrinolysis Inhibitor Activation,”J. Biol. Chem. 275, 22942-47, Jul. 28, 2000.
Bitonti et al., Pulmonary Delivery of an Erythropoietin Fc Fusion Protein in Non-human Primates Through an Immunoglobulin Transport Pathway,Proc. Natl. Acad. Sci. USA 101, 9763-68, Jun. 29, 2004.
Dong et al., “P-selectin-targeting of the Fibrin Selective Thrombolytic Desmodus Rotundus Salivary Plasminogen Activator α1,”Thrombl Haemost. 92, 956-65, 2004.
Adams et al., “Thrombin-cofactor Interactions: structural Insights into Regulatory Mechanisms,”Arteriosclerosis, Thrombosis, and Vascular Biology 26, 1738-45, May 25, 2006.
Dahlback et al., “Blood Coagulation,”The Lancet 355, 1627-32, May 6, 2000.
Faelber et al., “The 1.85 Å Resolution Crystal Structures of Tissue factor in Complex with Humanized Fab D3h44 and of Free Humanized Fab D3h44: Revisiting the Solvation of antigen combining Sites,”J. Mol. Biol. 313, 83-97, 2001.
Haber et al., “Antibody Targeting as a Thrombolytic strategy,”Ann. NY Acad. Sci. 667, 365-81, 1992.
Moons et al., “Tissue Factor and Coronary Artery Disease,”Cardiovascular Res. 53, 313-25, 2002.
Gresele et al., “Novel Approaches to the Treatment of Thrombosis,”Tresnds Pharmacol. Sci. 23, 25-32, 2002.
Esmon, “Regulation of Blood Coagulation,”Biochim. Biophys. Acta 1477, 349-60, 2000.
Esmon, “The Roles of Protein C and Thrombomodulin in the Regulation of Blood Coagulation,”J. Biol. chem. 264, 4743-4846, 1989.
Chapman et al., “Therapeutic antibody fragments with prolonged in vivo half-lives,”Nature Biotechnology 17, 780-83, 1999.
Harlow et al.,Antibodies, A Laboratory Manual, Harlow & Lane, eds., Cold Spring Harbor Laboratory, 1988, pp. 340-341.
Heyman et al., “Carbohydrate Chains on IgG2b: A Requirement for Efficient Feedback Immunosuppression,”J. Immunol. 134, 4018-23, 1985.

Affiliated with

Also associated with

Rating

Polynucleotides encoding anticoagulant fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polynucleotides encoding anticoagulant fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polynucleotides encoding anticoagulant fusion proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4061407